Digma aims to harness the power of the duodenum to empower patients and physicians with safe, simple and effective new therapies for type 2 diabetes that enable them to live longer, healthier and happier lives.The company is developing a minimally invasive therapy, Endoscopic Glycemic Management (EGM), that aims to restore the body’s natural ability to control blood glucose levels.

The treatment targets the duodenal submucosa which is central to nutrient sensing and metabolic signaling.The product consists of a console and a single-use catheter that is compatible with the working channel of standard gastrointestinal endoscopes.

The EGM procedure is being developed so that it can be performed in a standard GI endoscopy suite without requiring additional imaging equipment.

The goal is to provide patients with durable improvement in glycemic control with minimal side effects and without requiring additional daily medical therapy.